Advanced search
1 file | 2.17 MB Add to list

Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis

An-Sofie Goessaert (UGent) and Karel Everaert (UGent)
Author
Organization
Abstract
Evidence for the efficacy and safety of intravesical onabotulinum toxin A (onabotA) injections has led to it being licensed in many countries in patients with urinary incontinence due to neurogenic detrusor overactivity resulting from spinal cord injury and multiple sclerosis, who are refractory or intolerant to the gold-standard treatment, anticholinergics. Owing to its mechanism of action, an inhibitory effect on acetylcholine release is obtained for up to 10 months, with a recommended dose of 200 units. Urinary tract infections and postvoid residual volume are the most prevalent side effects. In the case of residual volume, clean intermittent catheterization might be necessary. In patients with spinal cord injury and multiple sclerosis, it is recommended to evaluate the manual dexterity and cognitive function before onabotA injections, to ensure that the patient and caregiver are able to perform catheterization if necessary. OnabotA treatment has a beneficial effect not only on urinary symptoms but also on quality of life.
Keywords
multiple sclerosis, onabotulinum toxin A, efficacy, quality of life, safety, spinal cord injury, synaptic vesicle glycoprotein 2 receptors, BOTULINUM-A TOXIN, LOWER URINARY-TRACT, CLEAN INTERMITTENT CATHETERIZATION, OF-THE-LITERATURE, SPHINCTER DYSSYNERGIA, SELF-CATHETERIZATION, BLADDER DYSFUNCTION, AUTONOMIC DYSREFLEXIA, COGNITIVE IMPAIRMENT, CONTROLLED-TRIAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.17 MB

Citation

Please use this url to cite or link to this publication:

MLA
Goessaert, An-Sofie, and Karel Everaert. “Onabotulinum Toxin A for the Treatment of Neurogenic Detrusor Overactivity Due to Spinal Cord Injury or Multiple Sclerosis.” EXPERT REVIEW OF NEUROTHERAPEUTICS 12.7 (2012): 763–775. Print.
APA
Goessaert, A.-S., & Everaert, K. (2012). Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. EXPERT REVIEW OF NEUROTHERAPEUTICS, 12(7), 763–775.
Chicago author-date
Goessaert, An-Sofie, and Karel Everaert. 2012. “Onabotulinum Toxin A for the Treatment of Neurogenic Detrusor Overactivity Due to Spinal Cord Injury or Multiple Sclerosis.” Expert Review of Neurotherapeutics 12 (7): 763–775.
Chicago author-date (all authors)
Goessaert, An-Sofie, and Karel Everaert. 2012. “Onabotulinum Toxin A for the Treatment of Neurogenic Detrusor Overactivity Due to Spinal Cord Injury or Multiple Sclerosis.” Expert Review of Neurotherapeutics 12 (7): 763–775.
Vancouver
1.
Goessaert A-S, Everaert K. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. EXPERT REVIEW OF NEUROTHERAPEUTICS. 2012;12(7):763–75.
IEEE
[1]
A.-S. Goessaert and K. Everaert, “Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis,” EXPERT REVIEW OF NEUROTHERAPEUTICS, vol. 12, no. 7, pp. 763–775, 2012.
@article{3158167,
  abstract     = {Evidence for the efficacy and safety of intravesical onabotulinum toxin A (onabotA) injections has led to it being licensed in many countries in patients with urinary incontinence due to neurogenic detrusor overactivity resulting from spinal cord injury and multiple sclerosis, who are refractory or intolerant to the gold-standard treatment, anticholinergics. Owing to its mechanism of action, an inhibitory effect on acetylcholine release is obtained for up to 10 months, with a recommended dose of 200 units. Urinary tract infections and postvoid residual volume are the most prevalent side effects. In the case of residual volume, clean intermittent catheterization might be necessary. In patients with spinal cord injury and multiple sclerosis, it is recommended to evaluate the manual dexterity and cognitive function before onabotA injections, to ensure that the patient and caregiver are able to perform catheterization if necessary. OnabotA treatment has a beneficial effect not only on urinary symptoms but also on quality of life.},
  author       = {Goessaert, An-Sofie and Everaert, Karel},
  issn         = {1473-7175},
  journal      = {EXPERT REVIEW OF NEUROTHERAPEUTICS},
  keywords     = {multiple sclerosis,onabotulinum toxin A,efficacy,quality of life,safety,spinal cord injury,synaptic vesicle glycoprotein 2 receptors,BOTULINUM-A TOXIN,LOWER URINARY-TRACT,CLEAN INTERMITTENT CATHETERIZATION,OF-THE-LITERATURE,SPHINCTER DYSSYNERGIA,SELF-CATHETERIZATION,BLADDER DYSFUNCTION,AUTONOMIC DYSREFLEXIA,COGNITIVE IMPAIRMENT,CONTROLLED-TRIAL},
  language     = {eng},
  number       = {7},
  pages        = {763--775},
  title        = {Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis},
  url          = {http://dx.doi.org/10.1586/ERN.12.61},
  volume       = {12},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: